Navigation Links
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
Date:11/5/2007

60% of second line HRPC patients on TPI 287 show clinical benefit

BOULDER, Colo., Nov. 5 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) announced today financial results for the third quarter ended September 26, 2007.

The net loss for the third quarter of 2007 was $6.1 million, or $0.37 per share. This compares to a net loss for the third quarter of 2006 of $3.6 million, or $0.22 per share. Included in the net loss for the third quarter of 2007 and 2006 is non-cash equity compensation expense totaling $869,000 and $615,000, respectively.

The net loss for the nine-months ended September 26, 2007 was $16.7 million, or $1.01 per share. This compares to a net loss for the nine-months ended September 27, 2006 of $12.1 million, or $1.03 per share. Included in the net loss for the nine-months ended September 26, 2007 and September 27, 2006 is non-cash equity compensation expense totaling $2.6 million and $2.5 million, respectively.

As of September 26, 2007, Tapestry had $9.4 million in cash, cash equivalents, and short-term investments.

Preliminary Results from Phase 2 Prostate Cancer Study

Tapestry also reported today on the first five evaluable patients in its Phase 2 prostate cancer trial. The trial is a multi-center, open label, two arm Phase 2 study for up to 80 patients who have failed prior docetaxel therapy for their disease.

Two patients who received previous benefit from prior docetaxel therapy enrolled in Arm 1 of the trial, and three patients who had no response to prior docetaxel therapy enrolled in Arm 2 of the study.

The two patients in Arm 1 of the study evidenced a stable disease lasting 8 cycles and a confirmed partial response, meas
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  AsureQuality and Ubiquitome ... testing for applications in food and primary production ... powered real-time PCR device, the Freedom4. ... through to the supermarket shelf for producers, processors ... involvement in animal disease control and pest management ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... Sigma-Aldrich (Nasdaq: SIAL ) announced today it has ... Your Favorite Gene powered by Ingenuity ( http://www.sigma-aldrich.com/yfg ... provides scientists access to dynamic gene-based content that they can ... of previously published scientific literature. , , "Your Favorite ...
... of Prophylaxis Therapy Label to Include Patient Labeling for Self-Administration ... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that ... Food and Drug Administration (FDA) related to its supplemental Biologics ... a treatment for acute attacks of hereditary angioedema (HAE). ...
... Kornberg Associates | Architects ( www.kornberg.com ) ... the new Malaysia Genome Institute. Ken Kornberg, president and ... The Malaysia Genome Institute (GENOMalaysia; http://genome.ukm.my/ ) is ... government in April 2005. The institute, located in ...
Cached Biology Technology:Sigma-Aldrich Honored With CIO 100 Award for Innovative Web Research Tool, Your Favorite Gene powered by Ingenuity 2Sigma-Aldrich Honored With CIO 100 Award for Innovative Web Research Tool, Your Favorite Gene powered by Ingenuity 3ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 2ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 3ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 4ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema 5Kornberg Associates Architects Selected to Design Research Areas of Malaysia Genome Institute 2
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... Queen Mary, University of London celebrates distinguished government scientist ... of the College this week. Chief Scientific Advisor ... (Defra) and notable Queen Mary alumnus, Professor Watson is ... science issues including ozone depletion and global warming. ...
... in Spanish . Agricultural Research ... an existing method for removing contaminants from storm water ... against runoff containing pollutants from point sources such as ... "Filter socks" containing compost tucked into mesh ...
... University of British Columbia zoologist has discovered a new ... and one of the earliest vertebrates dating back 500 ... evolution of steroid hormones and may help conservation and ... significant scientific implications and application for lamprey conservation," says ...
Cached Biology News:Honorary Fellowship awarded to government Chief Scientific Advisor 2'Super socks' help stem pollution runoff 2UBC researcher discovers ancient 'stress hormone' in pre-historic fish 2
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
LAL Chromogenic Endpoint assay...
RayBio Human Atherosclerosis Antibody Array 1.1 (4) with Accessory, detects 40 inflammatory factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Request Info...
Biology Products: